These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 35752131)
1. Plasma biomarkers of brain injury in COVID-19 patients with neurological symptoms. Sahin BE; Celikbilek A; Kocak Y; Saltoglu GT; Konar NM; Hizmali L J Neurol Sci; 2022 Aug; 439():120324. PubMed ID: 35752131 [TBL] [Abstract][Full Text] [Related]
2. NRGN, S100B and GFAP levels are significantly increased in patients with structural lesions resulting from mild traumatic brain injuries. Çevik S; Özgenç MM; Güneyk A; Evran Ş; Akkaya E; Çalış F; Katar S; Soyalp C; Hanımoğlu H; Kaynar MY Clin Neurol Neurosurg; 2019 Aug; 183():105380. PubMed ID: 31234132 [TBL] [Abstract][Full Text] [Related]
3. Diagnostic value of serum glial fibrillary acidic protein and S100B serum levels in emergency medicine patients with traumatic versus nontraumatic intracerebral hemorrhage. Aydin I; Algin A; Poyraz MK; Yumrutas O Niger J Clin Pract; 2018 Dec; 21(12):1645-1650. PubMed ID: 30560830 [TBL] [Abstract][Full Text] [Related]
4. Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Vos PE; Lamers KJ; Hendriks JC; van Haaren M; Beems T; Zimmerman C; van Geel W; de Reus H; Biert J; Verbeek MM Neurology; 2004 Apr; 62(8):1303-10. PubMed ID: 15111666 [TBL] [Abstract][Full Text] [Related]
5. Brain injury markers: S100 calcium-binding protein B, neuron-specific enolase and glial fibrillary acidic protein in children with diabetic ketoacidosis. Çatlı G; Anık A; Acar S; Küme T; Karabulut M; Çalan ÖG; Dündar BN; Abacı A Pediatr Diabetes; 2018 Aug; 19(5):1000-1006. PubMed ID: 29484801 [TBL] [Abstract][Full Text] [Related]
6. Glial Fibrillary Acidic Protein (GFAP) Outperforms S100 Calcium-Binding Protein B (S100B) and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1) as Predictor for Positive Computed Tomography of the Head in Trauma Subjects. Mahan MY; Thorpe M; Ahmadi A; Abdallah T; Casey H; Sturtevant D; Judge-Yoakam S; Hoover C; Rafter D; Miner J; Richardson C; Samadani U World Neurosurg; 2019 Aug; 128():e434-e444. PubMed ID: 31051301 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of prehospital serum S100B and GFAP in patients with mild traumatic brain injury: a prospective observational multicenter cohort study - "the PreTBI I study". Seidenfaden SC; Kjerulff JL; Juul N; Kirkegaard H; Møller MF; Münster AB; Bøtker MT Scand J Trauma Resusc Emerg Med; 2021 Jun; 29(1):75. PubMed ID: 34078435 [TBL] [Abstract][Full Text] [Related]
8. GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. Pelinka LE; Kroepfl A; Leixnering M; Buchinger W; Raabe A; Redl H J Neurotrauma; 2004 Nov; 21(11):1553-61. PubMed ID: 15684648 [TBL] [Abstract][Full Text] [Related]
9. The role of S100B protein, neuron-specific enolase, and glial fibrillary acidic protein in the evaluation of hypoxic brain injury in acute carbon monoxide poisoning. Akdemir HU; Yardan T; Kati C; Duran L; Alacam H; Yavuz Y; Okuyucu A Hum Exp Toxicol; 2014 Nov; 33(11):1113-20. PubMed ID: 24505052 [TBL] [Abstract][Full Text] [Related]
10. Modeling the Kinetics of Serum Glial Fibrillary Acidic Protein, Ubiquitin Carboxyl-Terminal Hydrolase-L1, and S100B Concentrations in Patients with Traumatic Brain Injury. Welch RD; Ellis M; Lewis LM; Ayaz SI; Mika VH; Millis S; Papa L J Neurotrauma; 2017 Jun; 34(11):1957-1971. PubMed ID: 28031000 [TBL] [Abstract][Full Text] [Related]
11. Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations. Petzold A; Eikelenboom MJ; Gveric D; Keir G; Chapman M; Lazeron RH; Cuzner ML; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G Brain; 2002 Jul; 125(Pt 7):1462-73. PubMed ID: 12076997 [TBL] [Abstract][Full Text] [Related]
12. S100B and Glial Fibrillary Acidic Protein as Indexes to Monitor Damage Severity in an In Vitro Model of Traumatic Brain Injury. Di Pietro V; Amorini AM; Lazzarino G; Yakoub KM; D'Urso S; Lazzarino G; Belli A Neurochem Res; 2015 May; 40(5):991-9. PubMed ID: 25898931 [TBL] [Abstract][Full Text] [Related]
13. Ability of Serum Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and S100B To Differentiate Normal and Abnormal Head Computed Tomography Findings in Patients with Suspected Mild or Moderate Traumatic Brain Injury. Welch RD; Ayaz SI; Lewis LM; Unden J; Chen JY; Mika VH; Saville B; Tyndall JA; Nash M; Buki A; Barzo P; Hack D; Tortella FC; Schmid K; Hayes RL; Vossough A; Sweriduk ST; Bazarian JJ J Neurotrauma; 2016 Jan; 33(2):203-14. PubMed ID: 26467555 [TBL] [Abstract][Full Text] [Related]
14. EPO treatment does not alter acute serum profiles of GFAP and S100B after TBI: A brief report on the Australian EPO-TBI clinical trial. Hellewell SC; Conquest A; Little L; Vallance S; Board J; Bellomo R; Cooper DJ; Morganti-Kossmann MC J Clin Neurosci; 2020 Jun; 76():5-8. PubMed ID: 32331937 [TBL] [Abstract][Full Text] [Related]
15. Increased GFAP concentrations in the cerebrospinal fluid of patients with unipolar depression. Michel M; Fiebich BL; Kuzior H; Meixensberger S; Berger B; Maier S; Nickel K; Runge K; Denzel D; Pankratz B; Schiele MA; Domschke K; van Elst LT; Endres D Transl Psychiatry; 2021 May; 11(1):308. PubMed ID: 34021122 [TBL] [Abstract][Full Text] [Related]
16. Post-cardiac arrest serum levels of glial fibrillary acidic protein for predicting neurological outcome. Larsson IM; Wallin E; Kristofferzon ML; Niessner M; Zetterberg H; Rubertsson S Resuscitation; 2014 Dec; 85(12):1654-61. PubMed ID: 25260722 [TBL] [Abstract][Full Text] [Related]
17. S100B vs. "GFAP and UCH-L1" assays in the management of mTBI patients. Oris C; Bouillon-Minois JB; Kahouadji S; Pereira B; Dhaiby G; Defrance VB; Durif J; Schmidt J; Moustafa F; Bouvier D; Sapin V Clin Chem Lab Med; 2024 Apr; 62(5):891-899. PubMed ID: 38033294 [TBL] [Abstract][Full Text] [Related]
18. Association of Very Early Serum Levels of S100B, Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and Spectrin Breakdown Product with Outcome in ProTECT III. Frankel M; Fan L; Yeatts SD; Jeromin A; Vos PE; Wagner AK; Wolf BJ; Pauls Q; Lunney M; Merck LH; Hall CL; Palesch YY; Silbergleit R; Wright DW J Neurotrauma; 2019 Oct; 36(20):2863-2871. PubMed ID: 30794101 [TBL] [Abstract][Full Text] [Related]
19. Brain damage serum biomarkers induced by COVID-19 in patients from northeast Brazil. Silva RC; da Rosa MM; Leão HI; Silva EDL; Ferreira NT; Albuquerque APB; Duarte GS; Siqueira AM; Pereira MC; Rêgo MJBM; Pitta MGR J Neurovirol; 2023 Apr; 29(2):180-186. PubMed ID: 36719594 [TBL] [Abstract][Full Text] [Related]
20. S100B as a glial cell marker in diabetic peripheral neuropathy. Celikbilek A; Akyol L; Sabah S; Tanik N; Adam M; Celikbilek M; Korkmaz M; Yilmaz N Neurosci Lett; 2014 Jan; 558():53-7. PubMed ID: 24211224 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]